- Home
- VIVS vs LRHC Comparison
VIVS vs LRHC Comparison
Compare VIVS & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- LRHC
- Stock Information
- Founded
- VIVS 2007
- LRHC 2004
- Country
- VIVS United States
- LRHC United States
- Employees
- VIVS N/A
- LRHC N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- LRHC
- Sector
- VIVS Health Care
- LRHC
- Exchange
- VIVS Nasdaq
- LRHC Nasdaq
- Market Cap
- VIVS 4.7M
- LRHC 5.4M
- IPO Year
- VIVS N/A
- LRHC 2023
- Fundamental
- Price
- VIVS $2.51
- LRHC $6.61
- Analyst Decision
- VIVS
- LRHC
- Analyst Count
- VIVS 0
- LRHC 0
- Target Price
- VIVS N/A
- LRHC N/A
- AVG Volume (30 Days)
- VIVS 763.1K
- LRHC 37.5K
- Earning Date
- VIVS 11-07-2025
- LRHC 08-18-2025
- Dividend Yield
- VIVS N/A
- LRHC N/A
- EPS Growth
- VIVS N/A
- LRHC N/A
- EPS
- VIVS N/A
- LRHC N/A
- Revenue
- VIVS $142,000.00
- LRHC $78,037,079.00
- Revenue This Year
- VIVS $42.38
- LRHC N/A
- Revenue Next Year
- VIVS $15.42
- LRHC N/A
- P/E Ratio
- VIVS N/A
- LRHC N/A
- Revenue Growth
- VIVS 94.52
- LRHC 54.92
- 52 Week Low
- VIVS $1.41
- LRHC $4.33
- 52 Week High
- VIVS $21.96
- LRHC $142.40
- Technical
- Relative Strength Index (RSI)
- VIVS 63.18
- LRHC 56.41
- Support Level
- VIVS $1.83
- LRHC $5.57
- Resistance Level
- VIVS $3.10
- LRHC $6.12
- Average True Range (ATR)
- VIVS 0.33
- LRHC 0.48
- MACD
- VIVS 0.06
- LRHC 0.19
- Stochastic Oscillator
- VIVS 57.25
- LRHC 94.51
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.